Abstract:The effective combination of drugs promoting antiangiogenesis and apoptosis effects has proven to be a promising collaborative tumor antidote; and the codelivery of small interfering RNA (siRNA) and chemotherapy agents within one efficient vehicle has gained more attention over single regimen administration. Herein, vascular endothelial growth factor specific siRNA (siVEGF) and paclitaxel (PTX) were introduced as therapeutic companions and coencapsulated into naturally mimic high-density lipoproteins (rHDL/siVEGF-PTX), so that various mechanisms of treatment can occur simultaneously. The terminal nanoparticles share capacity of specific-targeting to tumor cells overexpressed scavenger receptor class B type I (SR-BI) and deliver siVEGF and PTX into cytoplasm by a nonendocytosis mechanism. By exchanging HDL core lipids with hydrophobic therapeutics, rHDL/siVEGF-PTX possessed particle size of ∼160 nm, surface potential of ∼-20 mV, and desirable long-term storage stability. In vitro results confirmed that the parallel activity of siVEGF and PTX displayed enhanced anticancer efficacy. The half-maximal inhibitory concentration (IC50) of rHDL/siVEGF-PTX toward human breast cancer MCF-7 cell is 0.26 μg/mL (PTX concentration), which presents a 14.96-fold increase in cytotoxicity by taking Taxol as comparison. Moreover, in vivo results further demonstrated that rHDL/siVEGF-PTX performed enhanced tumor growth inhibition via natural targeting pathway, accompanied by remarkable inhibition of neovascularization in situ caused by siVEGF silencing in down-regulation of VEGF proteins. On the premise of effective drug codelivery, rHDL/siVEGF-PTX demonstrated high tumor targeting for collaborative antitumor efficacy without side effects after systemic administration, and this bioinspired strategy could open an avenue for exploration of combined anticancer therapy.

Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer

Low-density Lipoprotein-Coupled Micelles with Reduction and Ph Dual Sensitivity for Intelligent Co-Delivery of Paclitaxel and Sirna to Breast Tumor

Trastuzumab-conjugated liposomes for co-delivery of paclitaxel and anti-abcb1 siRNA in HER2-positive breast cancer: In vitro and in vivo evaluations

Cytological Study in Vitro on Co-delivery of Sirna and Paclitaxel Within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

Microrna-200c Delivered by Solid Lipid Nanoparticles Enhances the Effect of Paclitaxel on Breast Cancer Stem Cell

Binary-copolymer System Base on Low-Density Lipoprotein-Coupled N-succinyl Chitosan Lipoic Acid Micelles for Co-Delivery MDR1 Sirna and Paclitaxel, Enhances Antitumor Effects Via Reducing Drug.

Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.

Co-Delivery of Sirna and Paclitaxel into Cancer Cells by Biodegradable Cationic Micelles Based on Pdmaema-Pcl-Pdmaema Triblock Copolymers

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer.

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

Natural Particulates Inspired Specific-Targeted Codelivery of Sirna and Paclitaxel for Collaborative Antitumor Therapy

Co-delivery of Paclitaxel and Survivin Sirna with Cationic Liposome for Lung Cancer Therapy

Liposome-based Co-Delivery of Sirna and Docetaxel for the Synergistic Treatment of Lung Cancer.

Co-delivery of Paclitaxel and Anti-Vegf Sirna by Tripeptide Lipid Nanoparticle to Enhance the Anti-Tumor Activity for Lung Cancer Therapy.

Co-delivery of siBcl-2 and PTX with mitochondria-targeted functions to overcoming multidrug resistance

Systemic Delivery of Micelles Loading with Paclitaxel Using N-succinyl-palmitoyl-chitosan Decorated with Crgdyk Peptide to Inhibit Non-Small-cell Lung Cancer

Fabrication and evaluation of chitosan-coated nanostructured lipid carriers for co-delivery of paclitaxel and PD-L1 siRNA

Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer

Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.

Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.